Indivior (NASDAQ:INDV) Insider Christian Heidbreder Sells 18,586 Shares of Stock

Indivior PLC (NASDAQ:INDV) insider Christian Heidbreder sold 18,586 shares of the stock in a transaction on Friday, July 10th. The shares were sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the sale, the insider owned 209,337 shares of the company’s stock, valued at approximately $8,612,124.18. This represents a 8.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Indivior Trading Down 0.7%

Shares of INDV traded down $0.28 during midday trading on Monday, reaching $40.22. The stock had a trading volume of 1,234,481 shares, compared to its average volume of 2,207,553. The firm has a market cap of $4.90 billion, a PE ratio of 20.63 and a beta of 0.86. The firm has a 50 day simple moving average of $38.52 and a 200-day simple moving average of $35.02. Indivior PLC has a one year low of $15.00 and a one year high of $42.81.

Indivior (NASDAQ:INDV) last issued its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The company had revenue of $317.00 million for the quarter. As a group, research analysts forecast that Indivior PLC will post 4.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Indivior

A number of institutional investors have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. raised its position in shares of Indivior by 43.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company’s stock valued at $11,395,000 after buying an additional 96,177 shares in the last quarter. Divisadero Street Capital Management LP boosted its position in shares of Indivior by 2,372.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock worth $81,072,000 after acquiring an additional 3,226,605 shares in the last quarter. Goldentree Asset Management LP bought a new position in Indivior in the third quarter valued at approximately $42,630,000. SG Americas Securities LLC increased its stake in Indivior by 752.2% in the fourth quarter. SG Americas Securities LLC now owns 412,197 shares of the company’s stock valued at $14,790,000 after acquiring an additional 363,829 shares during the last quarter. Finally, Yousif Capital Management LLC acquired a new position in Indivior during the fourth quarter valued at approximately $1,137,000. Institutional investors own 60.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on INDV shares. Barclays began coverage on Indivior in a research report on Thursday, June 18th. They issued an “overweight” rating and a $46.00 price objective for the company. Weiss Ratings cut shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Finally, Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Indivior currently has a consensus rating of “Moderate Buy” and an average target price of $40.29.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.